Vivoryon Therapeutics N.V. (AMS: VVY)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
2.060
+0.030 (1.48%)
Sep 4, 2024, 1:59 PM CET
-83.39%
Market Cap 54.74M
Revenue -3.62M
Net Income -28.34M
Shares Out 26.07M
EPS -1.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 106,664
Open 2.000
Previous Close 2.030
Day's Range 2.000 - 2.110
52-Week Range 0.410 - 12.860
Beta 1.88
Analysts n/a
Price Target n/a
Earnings Date Sep 13, 2024

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 15
Stock Exchange Euronext Amsterdam
Ticker Symbol VVY
Full Company Profile

News

There is no news available yet.